- Our Products
- Overview
- Partnering Search
- Company Profiling
- Partneringtools
- Reports
- Partnering Consulting
- Comparison
- Forums
- Visit our forums
- Jobs
- Visit our job site
- Case Studies
- See what others think about our service
- Newsletter
- Partnering update
- Key reports
- Subscribe
- Quick Links
- Profile now
- Register now
- Profiled companies
- Featured events
- Industry news
- PR Newswire New!
- Contact us
- Send an email
- Call us: +44 1904 520460
- Request a callback
- RSS Feeds
- Keep up to date
is a division of
- Industry news
- Financial Results
News of the day
DGAP-Ad-hoc: Biotest AG: strong first half year, profit target raised
Dreieich, 18 July 2008. According to preliminary figures, in the first half of 2008 Biotest achieved sales of EUR210.9 million, which represents a 33% increase year-on-year (EUR158.4 million). Earnings before interest and tax (EBIT) rose 52% to EUR27.6 million (2007: EUR18.2 million). At EUR14.4 million, Biotest's earnings after tax were up 53% in the first six months of 2008 compared with the same period in the previous year (EUR9.4 million). Sales and earnings also increased net of... moreMETabolic EXplorer Reports Second Quarter 2008 Revenues
Clermont-Ferrand, France, July 18th 2008 - METabolic EXplorer (Eurolist B: METEX), a green chemistry company that specializes in the development of bioprocesses for the production of chemical compounds used in a wide range of everyday products (paints, solvents, adhesives, textile fibres, resorbable surgical thread) announced today its revenues for the 2nd Quarter ending 30 June 2008. moreCubist Pharmaceuticals Reports First $100 Million Revenue Quarter; Q2 2008 Total Revenues $101.8 Million; Total Net Product Revenues $101.4 Million
LEXINGTON, Mass.--July 17, 2008--Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today reported its first $100 million revenue quarter. For the second quarter ended June 30, 2008, Cubist's net revenues from CUBICIN(R) (daptomycin for injection) increased 46% from the prior year, from $69.5 million in the second quarter of 2007 to $101.4 million in the second quarter of 2008. Total revenues for the second quarter of 2008 increased 46% over the second quarter of 2007 from $69.8 million in the second... moreIndustry news search
Most Viewed News
- IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007, Exceeding $75 Billion
- KV Pharmaceutical Company Reports Fiscal 2008 Results
- Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2008
- Interim results for the six months ended 31 March 2008
- POLYDEX REPORTS FIRST QUARTER FINANCIAL RESULTS SHAREHOLDER EQUITY OF COMPANY EXCEEDS CURRENT SHARE PRICE
- RSS Feed...
Recent news
To keep up to date with news from this category use our
Gilead Sciences Announces Second Quarter 2008 Financial Results
FOSTER CITY, Calif.-- July 17, 2008--Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the quarter ended June 30, 2008. Total revenues for the second quarter of 2008 were $1.28 billion,...
Strong financial results in the first half of 2008
July 17, 2008 -- Based on preliminary figures, Group sales increased 9 % in constant currency and by 2 % at actual rates to EUR 5,710 million. Group EBIT rose by 8 % in constant currency. At actual rates, EBIT was at...
Fresenius Medical Care Reports Preliminary Second Quarter and First Six Months 2008 Results
July 17, 2008 -- Fresenius Medical Care AG & Co. KGaA ("the Company"), the world's largest provider of dialysis products and services, today announced preliminary results for the second quarter and the first six months...
QLT ANNOUNCES SECOND QUARTER 2008 VISUDYNE® SALES
July 17, 2008 VANCOUVER, CANADA--QLT Inc. (NASDAQ:QLTI; TSX:QLT) today reported that Novartis AG announced global sales of QLT's Visudyne® (verteporfin) product of US$40.7 million for the second quarter ended June 30,...
ICU Medical, Inc. Reports Second Quarter 2008 Results
SAN CLEMENTE, Calif., July 17, 2008 -- ICU Medical, Inc., (Nasdaq:ICUI), a leading low cost manufacturer of safe medical connectors, custom medical products and critical care devices, today announced results for the...
Stryker Operating Results for Quarter Ended June 30, 2008
KALAMAZOO, Mich., July 17, 2008 -- Stryker Corporation (NYSE: SYK) reported operating results for the quarter ended June 30, 2008 as follows:
Novartis gains momentum with strong performance in first half of 2008 from portfolio focused on growth areas of healthcare
Basel, July 17, 2008 - Commenting on the results, Dr. Daniel Vasella, Chairman and CEO of Novartis said: "The growth acceleration in the second quarter of 2008 and our R&D successes, especially in Pharmaceuticals and...
Strong financial results in the first half of 2008
July 17, 2008 -- Based on preliminary figures, Group sales increased 9 % in constant currency and by 2 % at actual rates to EUR 5,710 million. Group EBIT rose by 8 % in constant currency. At actual rates, EBIT was at...
SALES & MARKETING UPDATE
July 16, 2008: Avita Medical Limited (ASX: AVH) is pleased to provide an update on the Company's sales and marketing activities. Unaudited full year results for the period ending 30 June 2008 confirm significant revenue...
MEDTOX Scientific Announces Second Quarter Results
ST. PAUL, Minn., July 16, 2008 -- MEDTOX Scientific, Inc. (Nasdaq:MTOX) today announced results for the second quarter ended June 30, 2008:
Abbott Reports Stronger-than-Expected Sales and Earnings Growth in Second Quarter and Raises Full-Year Outlook
Abbott Park, Illinois (NYSE: ABT) --July 16, 2008- Abbott today announced financial results for the second quarter ended June 30, 2008.
St. Jude Medical Reports Second Quarter Results
ST. PAUL, Minn. -- July 16, 2008 -- St. Jude Medical, Inc. (NYSE: STJ) today reported sales and net earnings for the second quarter ended June 28, 2008.
SGS 2008 Half Year Results
July 16, 2008 -- he SGS Group's posted constant currency revenue growth of 17% (10% reported basis) to CHF 2.3 billion and an operating profit of CHF 370 million, 14.2% up on the prior year.
Jubilant Organosys Reports Q1 FY09 Revenues growth of 53% to Rs. 826.6 crore; Pharma & Life Science revenues increase 72%; Q1 FY09 EBITDA increases 62% to Rs. 173.2 crore.
July 15, 2008 -- Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced its financial results for Q1 FY2009.
Aceto Corporation Announces Fourth Quarter Fiscal 2008 Sales Exceed $100 Million
LAKE SUCCESS, N.Y., Jul 15, 2008 -- Aceto Corporation (Nasdaq:ACET), a global leader in the sourcing, quality assurance, regulatory support, marketing and distribution of chemically derived pharmaceuticals,...
Lumera Corporation Announces Registered Direct Offering and Preliminary Q2 2008 Results
BOTHELL, Wash -- July 15, 2008--Lumera Corporation (NASDAQ:LMRA) today announced that the Company has entered into definitive agreements with selected institutional investors to sell 4 million shares of its common stock...
Johnson & Johnson Reports 2008 Second-Quarter Results:
New Brunswick, NJ (July 15, 2008) - Johnson & Johnson today announced record sales of $16.5 billion for the second quarter of 2008, an increase of 8.7% as compared to the second quarter of 2007. Operational growth was...
BIOPHAN REPORTS FIRST QUARTER 2008 RESULTS
PITTSFORD, NY--July 15, 2008 - Biophan Technologies, Inc. (OTC BB: BIPH.OB), a developer of next-generation biomedical technology, today announced the results of their operations for the first quarter ended May 31, 2008.
Simulations Plus (SLP) Reports Third Quarter and Nine Months FY2008 Financial Results
LANCASTER, Calif. -- July 15, 2008 -- Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of simulation and modeling software for pharmaceutical discovery and development, today reported financial results for its...
Genentech Announces Second Quarter 2008 Results
South San Francisco, Calif -- July 14, 2008 -- Genentech, Inc. (NYSE: DNA) today announced financial results for the second quarter of 2008. Key results for the second quarter of 2008 include:
Peregrine Pharmaceuticals Reports Financial Results for Fiscal Year 2008
TUSTIN, Calif., July 14, 2008 -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), today announced financial results for fiscal year (FY) 2008 ended April 30, 2008. Total revenues for FY 2008 increased 64% to $6,093,000,...
Kimberly-Clark Announces Preliminary Second Quarter 2008 Results
DALLAS, July 14, 2008 -- Kimberly-Clark Corporation (NYSE: KMB) today reported that net sales in the second quarter of 2008, based on preliminary figures, advanced 11 percent to $5.0 billion. Sales growth was...
Hi-Tech Pharmacal Reports Strong Sales and a Return to Profitability for the Fourth Fiscal Quarter 2008
AMITYVILLE, N.Y.-- July 11, 2008--Hi-Tech Pharmacal Co., Inc. (NASDAQ: HITK) today reported results for the quarter and fiscal year ended April 30, 2008.
ARIUS announces second quarter fiscal 2008 financial results
TORONTO, July 11- ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the second fiscal...
BSD Medical's Year-to-Date Sales Up 66% from Prior Year
SALT LAKE CITY, Utah July 10, 2008--BSD Medical Corp. (NASDAQ:BSDM) today announced that the company has filed its third quarter 10-Q report with the Securities and Exchange Commission and has released the following...
Merit Medical Pre-Announces Record Sales and Earnings for the Second Quarter Ended June 30, 2008
SOUTH JORDAN, Utah, July 10, 2008 -- Merit Medical Systems, Inc. (Nasdaq: MMSI), a leading manufacturer and marketer of proprietary disposable devices used primarily in cardiology and radiology procedures, announced...
THALLION ANNOUNCES 2008 SECOND QUARTER RESULTS
Montréal, July 10, 2008 - Thallion Pharmaceuticals Inc. (TSX: TLN) today announced its operational and financial results for the 2008 second quarter which ended on May 31, 2008.
ViRexx Announces Filing of Amended and Restated Audited Financial Statements for Year Ended December 31, 2007 and Amended and Restated Annual Report on Form 20-F
EDMONTON, ALBERTA-- July 10, 2008 - ViRexx Medical Corp. (TSX:VIR) (AMEX:REX), a company focused on immunotherapy treatments for certain cancers, chronic hepatitis B & C and embolotherapy treatments for tumours, today...
Chattem Reports Increase in Revenues and Earnings for the Second Quarter and First Six Months of Fiscal 2008
CHATTANOOGA, Tenn., Jul 10, 2008 -- Chattem, Inc. (NASDAQ: CHTT), a leading marketer and manufacturer of branded consumer products, today announced financial results for the second fiscal quarter and six months ended...
BIOMET ANNOUNCES FOURTH QUARTER AND FISCAL 2008 FINANCIAL RESULTS
WARSAW, Ind., July 10, 2008 - Biomet, Inc. announced today fourth quarter and fiscal 2008 financial results for the year ended May 31, 2008.
Vasogen Announces Second Quarter 2008 Results
Mississauga, Ontario - July 09, 2008 -- Vasogen Inc. (NASDAQ:VSGN; TSX:VAS) today reported the results of operations for the three and six months ended May 31, 2008. All dollar amounts referenced herein are in Canadian...
Theratechnologies Announces Financial Results and Highlights for the Second Quarter 2008
Montréal, Canada - July 9, 2008 - Theratechnologies (TSX:TH) today announced its financial results for the second quarter ended May 31, 2008 and reviewed recent corporate highlights.
ELITE PHARMACEUTICALS FILES ITS FORM 10-K FOR THE FISCAL YEAR ENDED MARCH 31, 2008 WITH THE SEC
Northvale, New Jersey, Tuesday, July 08, 2008: Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (AMEX: ELI), a specialty pharmaceutical company focused primarily on developing and commercializing proprietary abuse...
HearUSA Reports Record Revenues for Second Quarter 2008
WEST PALM BEACH, FL, July 08, 2008 -- HearUSA, Inc. (AMEX: EAR), the recognized leader in hearing care for the nation's top managed care providers through more than 190 company-owned hearing care centers and a network...
Vision-Sciences, Inc. Announces Results for Q4 and the Fiscal Year Ended March 31, 2008
ORANGEBURG, N.Y., July 1, 2008 -- Vision-Sciences, Inc., NasdaqCM:VSCI - News) (``Vision-Sciences'' or the ``Company''), today announced results for its fiscal fourth quarter (``Q4 08'') and fiscal year ended March 31,...
Axis-Shield 2008 Interims Pre-Close Trading Update
Dundee, Scotland, 30 June 2008: Axis-Shield (LSE:ASD, OSE:ASD), the international in-vitro diagnostics company, today issues the following update for the six months ending 30 June 2008, ahead of the Company's close...
Goldshield Grp PLC - Final Results
June 26, 2008 -- Goldshield Group plc ("Goldshield"), the Pharmaceutical and Consumer Health Company, today announces its preliminary results for the year ended 31 March 2008.
Cyanotech Reports Financial Results for the Fourth Quarter and Fiscal Year 2008
KAILUA KONA, Hawaii (June 26, 2008) -- Cyanotech Corporation (Nasdaq Capital Market: CYAN), a world leader in producing high-value nutrition and health products from microalgae, today announced financial results for the...
Interim results for the six months ended 31 March 2008
June 26, 2008-- Keele, UK: Cobra Biomanufacturing Plc (AIM: CBF), the international manufacturer of biopharmaceuticals, today announces its interim results for the six months ended 31 March 2008.
Gentium Reports First Quarter Financial Results; Provides Financial and Clinical Update
VILLA GUARDIA, Italy, June 26, 2008 -- Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported financial results for the quarter ended March 31, 2008. Highlights of the first quarter of 2008 and recent weeks...
SYGNIS reports full year financial results and reviews a year of solid progress
Heidelberg, 26 June 2008 - SYGNIS Pharma AG (Frankfurt: LIO; ISIN DE0005043509; Prime Standard) today reports its financial results for the period ended 31 March 2008. Fiscal year 2007/2008 was one in which SYGNIS...
Financial Results for the 12 months ended 31 December 2007
London, UK, 26 June, 2008 - Lipoxen PLC (AIM:LPX), a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, announces today its consolidated...
Rockwell Automation Provides Third Quarter Guidance
MILWAUKEE-June 25, 2008--Rockwell Automation, Inc. (NYSE: ROK) today announced that it expects to report third quarter diluted earnings per share of $0.93 - $1.00. Given the expected third quarter earnings, and what...
KV Pharmaceutical Company Completes Fiscal 2008 Filings with Securities and Exchange Commission
St. Louis, MO - June 25, 2008 - KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and...
CardioTech International Reports Fiscal 2008 Results
WILMINGTON, Mass.--June 25, 2008--CardioTech International, Inc. (AMEX: CTE), a leading developer and manufacturer of advanced biomaterials for a broad range of medical devices, today reported financial results for the...
Strong Results in Roundup, Seeds and Traits Businesses Propel Monsanto to Record Third-Quarter and Year-To-Date Results
June 25, 2008 -- Comment from Monsanto Chairman, President and Chief Executive Officer Hugh Grant:
Consort Medical Plc Final Results - Part 1
June 24, 2008-Consort Medical (LSE: CSRT), a leader in medical devices for inhaled drug delivery and anaesthesia, today announces its preliminary results for the 53 weeks to 3 May 2008.
Symmetry Medical Reports Record First Quarter 2008 Revenue of $101.9 Million
WARSAW, Ind., June 24, 2008 -- Symmetry Medical Inc. (NYSE: SMA), a leading independent provider of products to the global orthopaedic device industry and other medical markets, announced today first quarter 2008...
SONIC INNOVATIONS ANNOUNCES PRE-EARNING REVENUE PROJECTIONS FOR SECOND QUARTER 2008
Salt Lake City-June 23, 2008-Sonic Innovations, Inc. (NASDAQ: SNCI), the only U.S.-based publicly traded manufacturer of digital hearing aids, announced today that the Company projects second quarter revenue to be...
Synovics Pharmaceuticals, Inc. (SYVC.OB) Files Its Second Quarter, 2008 Form 10Q with the SEC
FORT LAUDERDALE, Fla., June 17, 2008 -- Synovics Pharmaceuticals, Inc. , a specialty pharmaceutical company, filed its second quarter, 2008 Quarterly Report with the Securities and Exchange Commission. Consolidated...
IMS Health Reports Global Biotech Sales Grew 12.5 Percent in 2007, Exceeding $75 Billion
NORWALK, CT, June 17, 2008 -- Global prescription sales of biotech drugs increased 12.5 percent in 2007 to more than $75 billion, according to a new report by IMS Health (NYSE: RX), the world's leading provider of...
KV Pharmaceutical Company Reports Fiscal 2008 Results
St. Louis, MO, June 16, 2008 - KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and...
IRIS EXPECTS TO MORE THAN TRIPLE REVENUES AND PROFITS IN CURRENT FIVE YEAR GROWTH PROGRAM, SHAREHOLDERS TOLD; FIRST FIVE YEAR PROGRAM WITNESSED 28% COMPOUND REVENUE GROWTH
CHATSWORTH, CA, June 13, 2008 - IRIS INTERNATIONAL, INC. (NASDAQ: IRIS), "expects to more than triple revenues and profits in the new five year growth initiative instituted as of the beginning of this year," César...
POLYDEX REPORTS FIRST QUARTER FINANCIAL RESULTS SHAREHOLDER EQUITY OF COMPANY EXCEEDS CURRENT SHARE PRICE
Toronto, Ontario, June 13, 2008 -- Polydex Pharmaceuticals Limited (NASDAQ:POLXF) has today reported financial results of operations for the first quarter of fiscal 2009, ending April 30, 2008.
PURE Bioscience (PURE) Reports Third Quarter and Nine-Month Results
SAN DIEGO, Calif.--June 13, 2008--PURE Bioscience (NASDAQ: PURE) today reported revenues for the third fiscal quarter ended April 30, 2008 of $416,500, an increase of 215% from $132,400 in the third quarter last year....
HELIX BIOPHARMA PRODUCT DEVELOPMENT UPDATE, QUARTERLY HIGHLIGHTS AND FINANCIAL RESULTS FOR FISCAL Q3 2008
June 11, 2008 -- (AURORA, Ontario) - Helix BioPharma Corp. (TSX, FSE: "HBP"), a biopharmaceutical company specializing in the field of cancer therapy, today announced its product development progress, quarterly...
Alfacell Reports Financial Results for Third Quarter of Fiscal 2008
SOMERSET, N.J., June 9 -- Alfacell Corporation (NASDAQ:ACEL) today reported its financial results for the third quarter of fiscal 2008.
BIOSENSORS ANNOUNCES FOURTH QUARTER AND FULL FINANCIAL YEAR RESULTS ENDED 31 MARCH 2008
Singapore 26 May 2008 - Biosensors International Group, Ltd. ("Biosensors" or the "Company", Bloomberg: BIG SP) today announced financial results for the fourth fiscal quarter ("4Q FY08") and the twelve months ended 31...
Oridion Reports Strong Revenue Growth of 34% and Increased Margins for First Quarter of 2008„$
Jerusalem/Needham - May 19, 2008 - Oridion Systems Ltd. (SWX: ORIDN) - achieved strong revenue growth of 34% and substantially increased profitability for the first quarter of 2008. Revenues amounted to USD 11.26...
ImaRx Therapeutics Reports First Quarter Ended 2008 Financial Results
TUCSON, Ariz., May 15, 2008 -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX), a biopharmaceutical company developing and commercializing therapies for vascular disorders, today reported financial results for the first quarter...
Mentor Reports Fourth Quarter and Full Year Financial Results for Fiscal Year 2008
SANTA BARBARA, Calif.-- May 15, 2008--Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, today announced financial results for the fourth quarter and full fiscal year...
Nymox Reports First Quarter 2008 Financial Results
HASBROUCK HEIGHTS, NJ (May 14, 2008) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today its financial results for the first quarter of 2008. Nymox reported a net loss of $1,232,063, or $0.04 per share for...
ULURU INC. REPORTS FIRST QUARTER 2008 FINANCIAL RESULTS
Addison, Texas, May 12, 2008; ULURU Inc. (AMEX: ULU) today reported financial results for the first quarter ended March 31, 2008. For the quarter ended March 31, 2008, the net loss attributable to common stockholders...
Celsion Corporation Reports First Quarter 2008 Results
COLUMBIA, Md., May 08, 2008--CELSION CORPORATION (NASDAQ: CLN) today announced financial results for the first quarter ended March 31, 2008. The Company reported a net loss of $4.1 million, or $0.40 per share, compared...
Targeted Genetics Reports First Quarter 2008 Financial Results
SEATTLE, WA, May 07, 2008 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced its financial results for the first quarter ended March 31, 2008. The Company will hold a conference call with analysts and...
Pain Therapeutics Announces First Quarter 2008 Financial Results
SAN MATEO, Calif., May 7, 2008 -- Pain Therapeutics, Inc. (Nasdaq:PTIE), a biopharmaceutical company, today reported financial results for the three months ended March 31, 2008. Net income for the quarter ended March...
QIAGEN Reports Strong First Quarter 2008 Results
Venlo, The Netherlands, May 5, 2008 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA) today announced the results of operations for its first quarter ended on March 31, 2008.
SONIC INNOVATIONS ANNOUNCES RESULTS FOR FIRST QUARTER 2008
Salt Lake City, Utah, May 1, 2008 -- Sonic Innovations, Inc. (NASDAQ: SNCI), a leading producer of advanced digital hearing aids, today announced results for the first quarter ended March 31, 2008.
INTERIM REPORT ON BIOTIE THERAPIES CORP. JANUARY 1 - MARCH 31, 2008
April 25, 2008--In January Lundbeck acquired the United Kingdom and Ireland rights for nalmefene from Britannia Pharmaceuticals (now part of STADA Group, headquartered in Germany). Following the new agreement Lundbeck...
Q4 FY08 Revenues grown 49% to Rs. 6,890 million; Net Profit at Rs. 582 million Pharma & Life Science revenues increase 102%
April 22, 2008 -- Jubilant Organosys Limited, an integrated pharmaceutical industry player and the largest Custom Research and Manufacturing Services Company in India, today announced its financial results for Q4/...
Annual Report and Accounts for the year to 31 December 2007
22 April 2008- 2007 saw the Group successfully complete a significant restructuring program that resulted in a radically improved trading position, more consistent revenue growth and a strong outlook for 2008. Revenue...
Fresenius SE: Q1 2008 - Successful start into 2008
April 30, 2008 -- Based on the Group's strong first quarter financial results Fresenius fully confirms its positive outlook for 2008: Group sales are expected to grow by 8 to 10 % in constant currency. Net income is...
ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
TUCSON, Ariz., March 31, 2008 -- ImaRx Therapeutics, Inc., a biopharmaceutical company developing and commercializing therapies for vascular disorders, today provided a corporate update along with fourth quarter and...
Aurobindo records consolidated Total Income of Rs 2530 crores and Net Profit of Rs.238 crores. Formulation business constitutes 39.4% of the net sales
March 31, 2008-Aurobindo Pharma Limited, is pleased to announce the financial results for the year ended 31st March 2008. The highlights are as under:
ImaRx Therapeutics Provides Business Update and Reports Third Quarter 2007 Financial Results
TUCSON, Ariz., November 08, 2007 -- ImaRx Therapeutics, Inc. (Nasdaq:IMRX) today provided a business update and reported financial results for the quarter and nine months ended September 30, 2007.
ImaRx Therapeutics Reports Second Quarter 2007 Financial Results and Provides Business Update
TUCSON, Ariz., August 29, 2007 -- ImaRx Therapeutics, Inc. (NASDAQ:IMRX) today reported financial results for the quarter and six months ended June 30, 2007, and provided a business update.
Stellar International Announces First Quarter 2004 Results; Revenue and Margins Climb, Loss Drops (US DOLLARS/USGAAP)
MAY 19, 2004 - LONDON, ONTARI - Stellar International Inc (TSXV:SLX / OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of low-cost therapeutics for aging populations, reported its results for the first...
CORRECTION FROM SOURCE: Stellar International Inc. Reports Revenue Growth Of 29.8% For The Year Ended December 31, 2003
APRIL 14, 2004 -LONDON, ONTARIO - Stellar International Inc. (TSXV:SLX; OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today...
Stellar International Inc. Reports Revenue Growth Of 29.8% For The Year Ended December 31, 2003
APRIL 13, 2004 - LONDON, ONTARIO - Stellar International Inc. (TSXV:SLX; OTCBB:SLRXF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today...
© Copyright 1995-2008 Pharmalicensing Ltd, is a division of 
All rights reserved. Terms and Conditions | Site map | Contact us